Carregando...
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease is refractory to at least one proteasome inhibito...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Principais autores: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7794172/ https://ncbi.nlm.nih.gov/pubmed/33179377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13592 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|